A Multicenter, Open-Label, Extension Clinical Trial to Evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis (PBC)
Latest Information Update: 06 Mar 2025
Price :
$35 *
At a glance
- Drugs Saroglitazar (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; Registrational
- Sponsors Zydus Pharmaceuticals (USA)
- 05 Sep 2024 Status changed from not yet recruiting to recruiting.
- 30 May 2024 Planned initiation date changed from 15 May 2024 to 15 Jun 2024.
- 27 May 2024 New trial record